3M Licenses Transdermal Patch for Stada
Stada licenses 3M's transdermal technology for a fentanyl patch.
3M Drug Delivery Systems reports that Stada Arzneimittel AG is licensing 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
The 3M Patent, which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.
Source: 3M Drug Delivery Systems
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
